Proliferative Diabetic Retinopathy
Conditions
Interventions
Intravitreal Brolucizumab
Sponsors
Gunma University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with proliferative diabetic retinopathy Patients aged 20 years or older Treatment naive for PDR Outpatients Patients who have provided written informed consent to participate in this study Patients who are not indicated for vitrectomy Patients who have chosen brolucizumab treatment using the treat-and-extend regimen Patients without diabetic macular edema
Exclusion criteria
Exclusion criteria: History of active intraocular or periocular infections, or idiopathic/autoimmune uveitis Patients suspected to have a history of retinal vasculitis or occlusive retinal vasculitis Patients with neovascular glaucoma Patients with a history of cerebral infarction or myocardial infarction within the past 6 months Patients deemed inappropriate for inclusion at the discretion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with a >=2-step improvement in ETDRS Diabetic Retinopathy Severity Score (DRSS) from baseline to Week 48 | — |
Countries
Japan
Contacts
Public ContactKazuma Saito
Gunma University Graduate School of Medicine Department of Ophthalmology
Outcome results
None listed